Effect of empagliflozin on weight in patients with prediabetes and diabetes
Abstract The impact of blood glucose-lowering medications on weight has always been a topic of interest in the treatment of diabetic patients. This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes. This quasi-experimental study was performed o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83820-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185561607766016 |
|---|---|
| author | Mojgan Sanjari Mohammad Hadavizadeh Narges Sadeghi Ahmad Naghibzadeh-Tahami |
| author_facet | Mojgan Sanjari Mohammad Hadavizadeh Narges Sadeghi Ahmad Naghibzadeh-Tahami |
| author_sort | Mojgan Sanjari |
| collection | DOAJ |
| description | Abstract The impact of blood glucose-lowering medications on weight has always been a topic of interest in the treatment of diabetic patients. This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes. This quasi-experimental study was performed on patients with prediabetes or type 2 diabetes with an HbA1c level up to 1% higher than the treatment target, and not using other blood glucose-lowering medications. Patients received 10 milligrams of Empagliflozin once daily for three months, and weight, BMI, waist circumference, and blood pressure were evaluated monthly. Forty-three patients (21 women and 22 men) enrolled. The average weight of patients decreased by 2.96 ± 1.96 kg (3.8%) (P < 0.001). BMI decreased by -1.10 ± 0.71 Kg/m2 (3.72%) (P < 0.001). The waist circumference of patients decreased by -3.23 ± 3.69 centimeters (P < 0.001). FPG decreased from 114.86 to 109.48 mg/dL (P < 0.001), and HbA1c decreased from 6.52% to 6.38% (P < 0.001). The weight change was more significant in men than women (-3.59 ± 1.74 vs. -2.30. ± 1.99), (P = 0.029). Weight reduction was greater in patients with GFR higher than 90 compared to GFR lower than 90 (-3.34. ± 2.00 vs. -2.16 ± 1.67) (P = 0.063). Also, no significant difference was observed in the weight, BMI, and waist circumference changes between different BMI groups (less than 25, 25 to 30, 30 to 35, and higher than 35). The trend of weight and BMI changes during the three-month empagliflozin treatment period was significant (P < 0.001) and didn’t reach a plateau level after three months. The change in waist circumference was also significant, reaching a plateau level after one month (P < 0.001). There was no significant change in blood pressure. In conclusion the weight, BMI, and waist circumference of patients decreased following the administration of empagliflozin. Weight reduction was more pronounced in males than females and in patients with a GFR above 90 than those with a GFR below 90. Trial registration: This study was approved by the Research Deputy of Kerman University of Medical Sciences with tracking number 401,000,516, IRCT code: IRCT20090317001774N10, and ethical code: IR.KMU.AH.REC.1402.065 was approved by Research Ethics Committee of Afzalipour Hospital- Kerman University of Medical Sciences. |
| format | Article |
| id | doaj-art-502249379dfc4e28b55c1c56786414fd |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-502249379dfc4e28b55c1c56786414fd2025-08-20T02:16:40ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-024-83820-7Effect of empagliflozin on weight in patients with prediabetes and diabetesMojgan Sanjari0Mohammad Hadavizadeh1Narges Sadeghi2Ahmad Naghibzadeh-Tahami3Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical SciencesPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical SciencesEndocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical SciencesHealth Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical SciencesAbstract The impact of blood glucose-lowering medications on weight has always been a topic of interest in the treatment of diabetic patients. This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes. This quasi-experimental study was performed on patients with prediabetes or type 2 diabetes with an HbA1c level up to 1% higher than the treatment target, and not using other blood glucose-lowering medications. Patients received 10 milligrams of Empagliflozin once daily for three months, and weight, BMI, waist circumference, and blood pressure were evaluated monthly. Forty-three patients (21 women and 22 men) enrolled. The average weight of patients decreased by 2.96 ± 1.96 kg (3.8%) (P < 0.001). BMI decreased by -1.10 ± 0.71 Kg/m2 (3.72%) (P < 0.001). The waist circumference of patients decreased by -3.23 ± 3.69 centimeters (P < 0.001). FPG decreased from 114.86 to 109.48 mg/dL (P < 0.001), and HbA1c decreased from 6.52% to 6.38% (P < 0.001). The weight change was more significant in men than women (-3.59 ± 1.74 vs. -2.30. ± 1.99), (P = 0.029). Weight reduction was greater in patients with GFR higher than 90 compared to GFR lower than 90 (-3.34. ± 2.00 vs. -2.16 ± 1.67) (P = 0.063). Also, no significant difference was observed in the weight, BMI, and waist circumference changes between different BMI groups (less than 25, 25 to 30, 30 to 35, and higher than 35). The trend of weight and BMI changes during the three-month empagliflozin treatment period was significant (P < 0.001) and didn’t reach a plateau level after three months. The change in waist circumference was also significant, reaching a plateau level after one month (P < 0.001). There was no significant change in blood pressure. In conclusion the weight, BMI, and waist circumference of patients decreased following the administration of empagliflozin. Weight reduction was more pronounced in males than females and in patients with a GFR above 90 than those with a GFR below 90. Trial registration: This study was approved by the Research Deputy of Kerman University of Medical Sciences with tracking number 401,000,516, IRCT code: IRCT20090317001774N10, and ethical code: IR.KMU.AH.REC.1402.065 was approved by Research Ethics Committee of Afzalipour Hospital- Kerman University of Medical Sciences.https://doi.org/10.1038/s41598-024-83820-7EmpagliflozinWeightWaist circumferenceBody mass indexDiabetesPrediabetes |
| spellingShingle | Mojgan Sanjari Mohammad Hadavizadeh Narges Sadeghi Ahmad Naghibzadeh-Tahami Effect of empagliflozin on weight in patients with prediabetes and diabetes Scientific Reports Empagliflozin Weight Waist circumference Body mass index Diabetes Prediabetes |
| title | Effect of empagliflozin on weight in patients with prediabetes and diabetes |
| title_full | Effect of empagliflozin on weight in patients with prediabetes and diabetes |
| title_fullStr | Effect of empagliflozin on weight in patients with prediabetes and diabetes |
| title_full_unstemmed | Effect of empagliflozin on weight in patients with prediabetes and diabetes |
| title_short | Effect of empagliflozin on weight in patients with prediabetes and diabetes |
| title_sort | effect of empagliflozin on weight in patients with prediabetes and diabetes |
| topic | Empagliflozin Weight Waist circumference Body mass index Diabetes Prediabetes |
| url | https://doi.org/10.1038/s41598-024-83820-7 |
| work_keys_str_mv | AT mojgansanjari effectofempagliflozinonweightinpatientswithprediabetesanddiabetes AT mohammadhadavizadeh effectofempagliflozinonweightinpatientswithprediabetesanddiabetes AT nargessadeghi effectofempagliflozinonweightinpatientswithprediabetesanddiabetes AT ahmadnaghibzadehtahami effectofempagliflozinonweightinpatientswithprediabetesanddiabetes |